The latest headlines across every section, pulled from official and open-access sources.
Nature Index’s latest research rankings show that China continues to be the clear leader in contributions to scientific journals, with a 22% increase between 2024 and 2025. While China remains well ahead of the rest of the top 10, nearly 10% growth in journal contributions from Japan and South Korea outpaced higher-ranked Western countries such as the U.S., Germany and the U.K.
The company's SPY002 prompted a 10.7-point reduction from baseline levels in patients’ Robart’s Histopathology Index (RHI) scores by week 12.
Executives told Fierce how the company is in the middle of a transition to “the new Biogen”—embracing partnerships, investment and entrepreneurship to replenish its pipeline.
Adaptive Biotechnologies is planning to separate its drug discovery and diagnostics businesses, outlining its intent to evaluate “strategic and structural alternatives” for the medicine wing of the company
AI drug design specialist Protillion has inked a $510 million biobucks collaboration and license agreement with Merck & Co. that brings together Protillion’s platform and Merck’s drug discovery expertise.
Medical device maker iRhythm has been hit by a cyberattack, but the company said the incident has not affected its core products, operations or ability to meet patient needs.
When compared with liberal oxygen therapy, conservative oxygen therapy did not improve rates of survival with favorable functional outcomes among unresponsive patients in the intensive care unit (ICU) receiving mechanical ventilation after cardiac arrest, according to results from the investigator-initiated, open-label LOGICAL trial published June 10 in NEJM.
Edgewise Therapeutics has reported phase 2 data on its cardiomyopathy prospect, keeping the biotech on track to start pivotal development of a would-be challenger to Bristol Myers Squibb and Cytokinetics.
In this interview, Clyde W. Yancy MD, MACC and Robert J. Mentz, MD, FACC examine definitions and treatment of ID in HF.
Supplementation with the vitamin K homologue menaquinone-7 (MK-7) significantly attenuated coronary artery calcification (CAC) compared with placebo in adults with symptomatic coronary artery disease (CAD), according to research published June 10 in JAMA Cardiology.
Administration of sodium bicarbonate made no significant difference in the sustained return of spontaneous circulation, compared with placebo, in patients who suffered an in-hospital cardiac arrest, according to research published June 11 in JAMA.
As biopharma companies of all stripes devote more time and attention to AI-based drug discovery and development, healthcare PE firm Altaris is bolstering its presence in the field through M&A.
The FDA gave the green light to Dexcom’s over-the-counter glucose monitor Stelo for children 2 years or older who don’t use insulin.
Lipid management remains a cornerstone of secondary prevention in atherosclerotic cardiovascular disease (ASCVD), with increasingly strong evidence supporting its central role across all vascular territories, including coronary, cerebrovascular, and peripheral arterial beds.
Eli Lilly is taking another shot at the pain market, continuing a recent M&A binge that shows no signs of slowing down.
With a panel of outside experts set to weigh in Thursday—and with a refusal-to-file fiasco with the FDA just barely in the rearview—Moderna and its contender for the United States’ first mRNA-based influenza vaccine are heading into a critical test this week.
In patients with atrial fibrillation (AFib) and left ventricular systolic dysfunction (LVSD), catheter ablation was associated with substantial improvement in LVEF regardless of late gadolinium enhancement (LGE) status, while 12-month LVEF and normalization rates were lower in patients with LGE present, according to results from the CAMERA-MRI II trial published June 8 in JACC: Clinical Electrophysiology.
Jazz Pharmaceuticals is looking to bolster its oncology research bona fides via a partnership with AbCellera to discover and develop T-cell-engaging (TCE) antibodies that could result in up to $820 million in biobucks for each program that Jazz options.
With pharma and life sciences deal values surpassing $65 billion in the first quarter, marking the strongest quarter in the industry since 2020, analysts from PwC have declared that the “biopharma ecosystem is back to full health.”
In this week’s View, Dr. Eagle highlights a study showing race and sex disparities in M-TEER outcomes, with Black patients presenting with more advanced disease, lower success, and higher heart failure readmissions than White patients, and women having lower success rates than men.
The FDA has pulled a U-turn on uniQure’s Huntington’s disease gene therapy, giving the biotech the OK to file for accelerated approval after previously demanding data from another trial.
Vedana Therapeutics has emerged from stealth with $46 million in series A financing aimed at advancing the company’s subcutaneously delivered antibodies for migraine prevention.
With neuronal data, AI models predicted grammar, meaning, and context of spoken sentences.
John Tsai, M.D., is rounding out his global drug development resume. Immediately after landing at Daiichi Sankyo, the pharma veteran finds himself leading the R&D portion of the antibody-drug conjugate specialist’s new five-year plan, which aims to lay the groundwork for Daiichi to become a global top 5 oncology company by 2035.